Category: News
Publication: An In-Depth Single-Gene Worldwide Carrier Frequency and Genetic Prevalence Analysis of CYP4V2 as the Cause of Bietti Crystalline Dystrophy
ReflectionBio joins forces with patient organization Invincible Vision ahead of World Rare Disease Day for Bietti’s Crystalline Dystrophy (BCD)
SAN FRANCISCO & HONG KONG–(BUSINESS WIRE)–Today, Invincible Vision and ReflectionBio® are launching their inaugural awareness and fundraising campaign, BY PATIENTS, FOR PATIENTS ™, for Bietti’s Crystalline Dystrophy (BCD).
HONG KONG & NEW YORK–(BUSINESS WIRE)–Reflection Biotechnologies Limited (“ReflectionBio”), a gene therapy company committed to the research and development of life-changing treatments for rare diseases, today announced that the U.S.
Rare Disease Patient CEO Joins “Orphan Drug Development Guidebook” Task Force
Richard Yang, Founder & CEO of ReflectionBio and a rare disease patient, was invited to join the newly formed “Orphan Drug Development Guidebook” Task Force of International Rare Diseases Research Consortium (IRDiRC).
ReflectionBio – By Patients, For Patients ®
Introduction Company News
Rare Disease Patient CEO Joins “Orphan Drug Development Guidebook” Task Force
(October 2018) Richard Yang, Founder & CEO of ReflectionBio and a rare disease patient, was invited to join the newly formed “Orphan Drug Development Guidebook” Task Force of International Rare Diseases Research Consortium (IRDiRC). The “Orphan Drug Development Guidebook” project aims at creating a simple guidebook for academic and industrial drug developers describing the available tools and initiatives specific for rare disease development and how to best use them.
“I am proud to be working with a group of international experts in the rare disease and orphan drug development field and sharing our experience. I will provide my perspective as an orphan drug developer and as a rare disease patient to facilitate the goal of the Task Force. I trust the collective efforts of the Task Force will benefit the rare disease patient community.” Richard Yang commented.
About the International Rare Diseases Research Consortium (IRDiRC): IRDiRC unites national and international governmental and non-profit funding bodies, companies (including pharmaceutical and biotech enterprises), umbrella patient advocacy organizations, and scientific researchers to promote international collaboration and advance rare diseases research worldwide. Importantly, the coverage of the Consortium is global and involves stakeholders from Africa, Asia, Australia, North America, and Europe.
For more information about IRDiRC’s “Orphan Drug Development Guidebook” Task Force,
please visit http://www.irdirc.org/activities/task-forces/orphan-drug-development-guidebook-task-force/
Patient-Driven Gene Therapy Company ReflectionBio® Receives Orphan Drug Designation From U.S. FDA For the Treatment of Bietti’s Crystalline Dystrophy (BCD).
HONG KONG & NEW YORK–(BUSINESS WIRE)–Reflection Biotechnologies Limited (“ReflectionBio”), a gene therapy company committed to the research and development of life-changing treatments for rare diseases, today announced that the U.S.
HONG KONG & NEW YORK–(BUSINESS WIRE)–Reflection Biotechnologies Limited (“ReflectionBio”), a gene therapy company committed to the research and development of life-changing treatments for rare diseases, today announced that the U.S.